<DOC>
	<DOCNO>NCT00988429</DOCNO>
	<brief_summary>The purpose study determine whether Eslicarbazepine acetate ( BIA 2-093 ) effective adjunct therapy treatment refractory partial seizure</brief_summary>
	<brief_title>Efficacy Safety Eslicarbazepine Acetate ( BIA 2-093 ) Adjunctive Therapy Refractory Partial Seizures</brief_title>
	<detailed_description>The study design include 3 part ; first part describe report . Part I study international , randomize , placebo-controlled , double-blind , parallel group , multicenter clinical study conduct 19 country 173 site 653 subject refractory simple partial complex partial seizure , without secondary generalization . After screen procedure confirm eligibility , subject enter Part I study , consist 3 period . The first period 8 week observation baseline period ( Week -8 Week -1 ) subject instructed complete seizure diary . At end 8 week observational baseline period , eligible subject randomize 1:1:1 allocation ratio 1 3 treatment group ( blind treatment assignment ) : - Placebo - ESL 800 mg QD - ESL 1200 mg QD Subjects enter second period Part 1 , 2 week , double blind , titration period ( Week 1 Week 2 ) . During period , subject ESL 800 mg group receive ESL 400 mg QD , subject ESL 1200 mg group receive ESL 800 mg QD , subject placebo group receive placebo QD . Subjects enter third period Part I , 12 week , double-blind , maintenance period ( Week 3 Week 14 ) subject ESL 800 mg group receive ESL 800 mg QD , subject ESL 1200 mg group receive ESL 1200 mg QD , subject placebo group receive placebo QD . At completion maintenance period , subject enter Part II taper study drug maintain blind accord follow titration procedure : subject 800 mg titrate 400 mg duration 2 week , subject 1200 mg titrate 800 mg 1 week down-titrated 400 mg 1 week subject placebo group receive placebo QD 2 week . During Part I , 1 2 concomitant AEDs allow study keep stable course study .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Inclusion Criteria At V1 ( screen ) , patient must be/have : 1 . Written inform consent sign patient . 2 . Aged 16 year ( patient 18 year age require parental/legal representative consent ) . In North America well participate country , appropriate and/or require state local law , minor patient must give write informed assent prior participation study . 3 . A documented diagnosis epilepsy since least 12 month prior screen . 4 . At least 4 partialonset seizure ( include subtypes simple partial , complex partial partial seizure evolve secondarily generalise ) 4 week prior screen . 5 . Currently treat 1 2 AEDs ( except OXC ) , stable dose regimen least 1 month prior screen . Patients use vigabatrin medication least 1 year deficit visual field identify ( confirmatory test available within 1 month study entry ) . The device VNS implant least 6 month screen ; parameter need stable least 1 month prior screen ( VNS count concomitant AED ) . 6 . Excepting epilepsy , patient judge general good health base medical history , physical examination finding , clinical laboratory test result . 7 . Postmenopausal otherwise incapable become pregnant reason surgery tubal ligation . In case woman childbearing potential ( WOCBP ) , patient must present serum betahuman chorionic gonadotropin ( BhCG ) test consistent non gravid state agree remain abstinent use reliable contraception ( hormonal contraception combine barrier method ) begin screen continue least PSV . At V2 ( randomisation ) , patient must : 8 . At least 8 partialonset seizure baseline least 3 partialonset seizure 4week section 8week baseline period prior randomisation ( documented diary ) seizurefree interval exceed 28 consecutive day . 9 . In case WOCBP , patient must present urine BhCG test consistent non gravid state . 10 . Diaries satisfactorily complete patient his/her caregiver . 11 . Satisfactorily comply study requirement baseline period ( include change concomitant AED therapy occur baseline period ) . Exclusion Criteria At V1 ( screen ) , patient must be/have : 1 . Only simple partial seizure motor symptomatology ( classified A2 4 accord International Classification Epileptic Seizures ) . 2 . Primarily generalise seizure . 3 . Known progressive neurological disorder ( progressive brain disease ; epilepsy secondary progressive cerebral lesion ) . 4 . Occurrence seizure close count accurately . 5 . History status epilepticus cluster seizure ( i.e. , 3 seizure within 30 minute ) within 3 month prior screen . 6 . Seizures nonepileptic origin . 7 . Seizures psychogenic origin within last 2 year . 8 . Major psychiatric disorder . 9 . Documented diagnosis schizophrenia accompany documented history least 1 acute psychosis episode within last 2 year ) history suicide attempt . 10 . Currently treat OXC . 11 . Using benzodiazepines occasional basis ( define 2 time per week ) , except use chronically AED . 12 . Known exposure Eslicarbazepine acetate previous study . Previous use Eslicarbazepine acetate participation clinical study Eslicarbazepine acetate ( patient expose Eslicarbazepine acetate [ e.g. , screen fail ] allow ) . 13 . Known hypersensitivity carboxamide derivative . 14 . History abuse alcohol , drug medication within last 2 year . 15 . Uncontrolled cardiac , renal , hepatic , endocrine , gastrointestinal , metabolic , haematological oncology disorder . 16 . Second thirddegree atrioventricular blockade correct pacemaker . 17 . Relevant clinical laboratory abnormality ( e.g. , sodium &lt; 130 mmol/L , alanine aspartate transaminase &gt; 2.0 time upper limit normal , white blood cell [ WBC ] count &lt; 3,000 cells/mm3 ) patient Asian ancestry , positive HLA B*1502 test . 18 . Estimated creatinine clearance &lt; 60 mL/min [ men : ( 140age ) x weight/serum creatinine x 72 ; woman : ( 0.85 ) ( 140age ) x weight/serum creatinine x 72 . Age year , weight kg , serum creatinine mg/dL ] . 19 . Pregnant nursing . 20 . Participation drug clinical trial within last 2 month receive investigational drug within 5 halflives product , whichever longer . Patient ( ) know take dos study drug ( ) early study ( y ) ( e.g . screenfailures ) allow without time limitation . 21 . Not ensured capability perform trial . 22 . Any condition circumstance , opinion Investigator , may compromise patient 's ability comply study protocol . 23 . Currently treat VNS , implant &lt; 6 month screen parameter stable least 1 month prior screen . At V2 ( randomisation ) , patient must be/have : 24 . Inadequate compliance concomitant AEDs 8week baseline period screen exclusion criterion . 25 . Inadequate completion study diary . 26 . Any condition circumstance , opinion Investigator , may compromise patient 's ability comply study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Refractory</keyword>
	<keyword>partial</keyword>
	<keyword>epilepsy</keyword>
	<keyword>efficacy</keyword>
	<keyword>eslicarbazepine</keyword>
	<keyword>safety</keyword>
</DOC>